Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from ProQR ( (PRQR) ) is now available.
On January 8, 2026, ProQR reported encouraging initial Phase 1 data for its lead candidate AX-0810, showing no serious safety issues and pharmacokinetics in line with preclinical findings after four weeks of dosing in the first cohort of healthy volunteers, with target engagement data expected in the first half of 2026 and plans to add a patient cohort thereafter. The company also selected development candidates AX-2402 for Rett syndrome and AX-2911 for MASH based on robust preclinical proof-of-concept data, highlighted non-clinical results suggesting disease-modifying potential versus existing approaches, and noted that milestone payments from its collaboration with Eli Lilly in 2025 support a cash runway into mid-2027 as it advances its Axiomer platform and executes its 2026 development and partnering agenda.
The most recent analyst rating on (PRQR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ProQR stock, see the PRQR Stock Forecast page.
Spark’s Take on PRQR Stock
According to Spark, TipRanks’ AI Analyst, PRQR is a Neutral.
ProQR’s overall stock score is primarily impacted by its financial performance and technical analysis. The company’s significant financial challenges, particularly in profitability and cash flow, are the most critical factors. Technical indicators suggest bearish momentum, and the valuation reflects ongoing losses. These factors collectively contribute to a lower overall stock score.
To see Spark’s full report on PRQR stock, click here.
More about ProQR
ProQR Therapeutics N.V., based in Leiden, Netherlands and Cambridge, Massachusetts, is a clinical-stage biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA base-editing platform. The company’s pipeline includes editing oligonucleotide candidates such as AX-0810 for cholestatic liver diseases, AX-2402 for Rett syndrome and AX-2911 for metabolic-associated steatohepatitis (MASH), targeting high unmet medical needs in both rare and prevalent genetic disorders.
Average Trading Volume: 547,604
Technical Sentiment Signal: Sell
Current Market Cap: $218.8M
For detailed information about PRQR stock, go to TipRanks’ Stock Analysis page.